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Introduction
Background on Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) is a recurring 
inflammatory condition caused by hyperkeratosis 
of the epithelial follicle, affecting apocrine-gland 
dense areas such as the axillae, inframammary areas, 
groin, and buttocks [1]. Obstruction of the apocrine/
sebaceous glands caused by excess production of 
sebum clogs the follicle and results in inflammation 
of the surrounding tissue [2]. Abscess formation 
is commonly seen and it can extend deep into the 
subcutaneous tissue, further promoting deep sinus 
tract formation. Hypertrophic scarring is a common 
sequela of the condition, primarily affecting those 
with darker skin tones.
Clinically HS presents as painful papules and nodules, 
eventually progressing to abscess formation and 
severe scarring. It may also be characterized by 
having a malodorous sterile discharge. The severity of 
the disease is described by the Hurley stages. Stage I 
exhibits few lesions; Stage II presents with abscesses 
and invasion with sinus tracts; Stage III designates 
full involvement of sinus tracts, along with many 
abscesses throughout the body [3]. Most cases are 
reported to be Hurley stages II-III [3].
HS is reported to affect 1% of the population and is 
more common in females than males [4]. It usually 
presents in the second and third decades of life. HS 
has a high association with smoking, obesity, Crohn 
disease and other auto-inflammatory diseases [5]. 
Among dermatological conditions, HS is known to 
be one of the most debilitating conditions, having a 
detrimental psychosocial impact on the individual’s 
life [5].
Background on hormonal therapy 
pathways
The pilosebaceous unit (consisting of hair, hair 
follicle, arrector pili muscles, and the sebaceous 
gland) is densely populated with sebaceous and 
apocrine glands in the axillae, groin, and buttocks 
area [1]. These glands have two types of androgen-
converting enzymes, 5-alpha-reductase type I and 
5-alpha-reductase type II [6]. Type I is found in both 
Abstract
Hidradenitis suppurativa is a recurrent inflammatory 
skin condition characterized by abscesses and boils, 
predominantly in the groin, armpit, and buttocks 
areas. HS is not a life-threatening condition, but 
severely impairs quality of life in those affected. 
Finding a successful treatment approach for HS has 
been challenging, in part because of the lack of a gold-
standard treatment method, limited research-based 
information, and the nature of clinical variation in the 
disease. Treatment commonly consists of antibiotics, 
anti-inflammatory therapy, hormonal therapy, and 
more invasive clinical procedures. Treatment is chosen 
by the degree of severity by which the condition 
presents and is modified accordingly. This review 
describes the roles of hormones in the pathogenesis 
of hidradenitis suppurativa and describes the use of 
hormonal therapy such as, finasteride, dutasteride, 
spironolactone, and oral contraceptives. The 
outcomes of the use of these modalities in various 
clinical studies are summarized.
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hair follicles and apocrine glands, whereas Type II is 
found only in hair follicles [6].
5a-reductase (5-AR) is best known for the conversion 
of testosterone into its more potent form, 
5-dihydroxytestosterone (5-DHT), [6]. Testosterone 
and 5-DHT bind to androgen receptors on the 
sebaceous gland, thus causing an increase in activity. 
This causes increased secretion of sebum and 
increased inflammation in the tissue.
Patients with HS were not found to have higher 
than normal plasma levels of testosterone or 5-DHT 
than normal individuals [7]. However, studies have 
demonstrated that the use of anti-androgenic 
medications has a favorable response in comparison 
to antibiotic based therapy alone [8,9].
Body of Article
Role of hormones
The role of sex hormones in the pathogenesis of 
HS remains unclear. The prevalence of HS is most 
often reported to be higher in women and changes 
in HS activity have been reported during times of 
fluctuating hormones such as during premenstrual 
periods, pregnancy, and menopause [10].
The age of onset of a disease can provide important 
clues into the association with hormonal changes. HS 
in children is rare [10]. Reported cases have occurred 
in normally developed children with no signs of 
hormonal aberrations such as premature menarche 
or adrenarche, although obesity was a commonly 
reported finding [11]. The condition seldom occurs 
before puberty and less than 2% of patients have 
onset of the disease before the age of 11 years. 
Studies analyzing the age of onset for HS found the 
most common time was between 11 and 30 years 
old [10]. One hypothesis is that adrenal androgen 
synthesis may be related to the peak time of onset 
and noted that cutaneous androgen enzyme activity 
Figure 1. Hidradenitis Suppurativa-The pilosebaceous unit is filled with sebaceous and apocrine glands that have two types of 
androgen-converting enzymes responsible for converting testosterone into 5-dihydrozytestosterone (5-DHT). Activation of androgen 
receptors in the gland then leads to increased sebum and inflammation. The role of hormones in HS is unclear but evidence supports a 
connection.
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is at its highest between 11 and 30 years old [10].
Premenstrual flares of HS reportedly occur in 
between 44-63% of patients [10]. Both estradiol and 
progesterone levels decline with the premenstrual 
period, suggesting HS is affected by the hormonal 
fluctuations of the menstrual cycle [12]. Further 
evidence favoring a hormonal influence in HS are the 
reported cases of exacerbation or resolution of HS 
during pregnancy when progesterone and estrogen 
levels rise. Regardless of whether authors describe 
improvement or worsening, most authors agree that 
disease activity is affected by pregnancy. This finding 
suggests hormonal surges are catalysts for clinical 
changes in the disease state. Although studies vary, 
the overall consensus indicates amelioration of HS 
during pregnancy and a deterioration post-partum 
[13-16]. The decline of estrogen and progesterone 
during menopause is associated with a decline in 
HS symptoms [17] and HS cases [18]. One study by 
Kromann et al. reported 48% of women experienced 
a decrease or complete resolution of HS and its 
symptoms with the onset of menopause [15]. 
Additionally, a second study found a substantial 
decrease of HS prevalence among people aged 55 
and older [19].
Progesterone and estrogens may influence HS 
through their effects on the immune system. 
Macrophages are present in HS lesions and 
overexpress Il-12 and Il-23, which induce a Th-17 
response. High levels of progesterone suppress 
the development and function of Th-17 cells [20]. 
Additionally, progesterone reduces TNF production 
of macrophages [21]. The role of estrogen on 
inflammation is not as well understood. Mouse 
studies suggest high levels of estrogen increase Il-
12 and induce a Th1 response leading to interferon 
gamma production, which is increased in HS [22].
Testosterone is the major circulating androgen. 
The role of androgens in HS remains unclear. One 
hypothesized role is that androgens may act through 
altering the immune response since activation 
of the androgen receptor increases macrophage 
production and TNF, leading to suppression of 
wound healing [23, 24]. Additionally, a second study 
found that a synthetic androgen, R1881, stimulated 
keratinocytes to produce TGF-Beta, a cytokine 
suspected to play a role in the pathogenesis of HS 
[25]. A study by Mortimer et al. compared blood levels 
of various hormones in patients with HS and age 
matched controls. Testosterone levels and androgen 
index in HS patients was increased compared to 
controls [16]. However, subsequent studies have 
reported conflicting results showing no difference 
in plasma testosterone or dehydroepiandrosterone 
levels between female patients with hidradenitis 
and controls [13,26]. Interestingly, patients with HS 
flares and controls showed no difference in hormone 
levels, whereas patients from the no-flare group 
had reduced progesterone and increased levels of 
testosterone, androstenedione, and androgen index 
[13].
The role of androgens remains unclear. Factors that 
continue to confound an understanding of the role 
of hormones include reports of the continuation 
and primary development of HS in postmenopausal 
women [27]. Furthermore, pregnancy and 
menstruation do not have consistent effects on the 
disease and hidradenitis is predominantly a disease 
of women. The relationship between androgen 
levels and the condition remains under discussion. 
Although there is no increase in serum androgens in 
most patients with HS, the mechanism may relate to 
altered end-organ sensitivity instead. The strongest 
supportive evidence for the role of androgens is the 
effectiveness of anti-androgen therapy.
Hormone therapy - Anti-androgens:
Finasteride
Finasteride is an antiandrogen that blocks 
5a-reductase type II and type III, thus blocking the 
conversion of testosterone to the more potent DHT. 
This drug, which is usually used in prostate cancer, 
has been used successfully for HS. Farrel et al. 
reported two cases of improvement in HS symptoms 
after 1 and 3 months of treatment with 5 mg/day of 
finasteride [28]. One of the reported case subjects 
was a 55-year-old postmenopausal woman who 
previously failed to respond to cyproterone acetate. 
Joseph et al. reported on 7 patients who experienced 
resolution or improvement in symptoms with 6-16 
weeks of treatment on 5 mg/day of finasteride 
[29]. Subsequently, Kraft and Searles demonstrated 
the superiority of finasteride over oral antibiotics. 
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Specifically, they reported on 41 women with HS 
refractory to antibiotics, retinoids, and surgery who 
showed 75% improvement, with 59% experiencing 
complete resolution. Side effects reported in the study 
were minimal with some swelling and menstrual 
irregularities. Lastly, Domenech et al. reported a 
case of a 28-year-old man with severe HS treated 
for one year who developed complete resolution of 
his symptoms on 5mg/day [30]. The precise means 
by which finasteride can improve symptoms in HS 
is unclear; many propose it acts by decreasing local 
concentrations of dihydrotestosterone at the level 
of the hair follicle by altering end-organ sensitivity 
rather than a more systemic effect on circulating 
androgen. An alternative hypothesis is an enhanced 
target tissue response to relatively normal androgen 
levels [8]. Although generally well tolerated by both 
sexes, finasteride is not without its own drawbacks. 
Multiple side effects including teratogenicity, 
decreased libido, erectile dysfunction, gynecomastia, 
and breast enlargement in women make it a less 
favorable option for many patients [31].
Dutasteride
Similarly, dutasteride (0.5 mg), has helped clear HS in 
both men and women in anecdotal cases. Dutasteride 
acts by blocking blocks 5a-reductase type I (which 
is most active in the skin) and type II. Dutasteride 
therapy reduces serum DHT significantly more 
than does finasteride. According to an experienced 
dermatologist’s anecdote, dutasteride and finasteride 
appear most useful in obese patients, whose disease 
is potentially more influenced by hormonal effects 
[32]. However, formal studies are lacking. The adverse 
event profiles of dutasteride and finasteride are 
similar and both can affect sexual function and lead 
to breast enlargement and tenderness [28]. Weak 
evidence suggests a difference in the onset of clinical 
benefit, although the available data does not confirm 
this finding. Similarly to finasteride, dutasteride must 
be used with caution given its teratogenicity.
Spironolactone
Spironolactone is a potassium-sparing diuretic 
with anti-androgen properties. The effectiveness of 
spironolactone has been mixed in various studies. In 
a study from Kraft and Searles, only 1 out of 5 patients 
taking spironolactone experienced improvement in 
symptoms [9]. More recently, in 2015, a case series 
of 20 women with HS treated with 100-150 mg 
spironolactone demonstrated notable results. Of 
the 20 patients, 17 reported improvements in their 
HS symptoms, 11 of which experienced complete 
resolution of disease as determined by a patient 
global assessment score designed for the study. 
Furthermore, they concluded spironolactone is 
an effective and safe long-term option for women 
with HS and found no advantage in concurrent 
treatment with tetracycline or OCP. Side effects of 
spironolactone included irregular periods (1 of 6) and 
heart palpitations (1 of 6) but the women continued 
adhering to the treatment regimen. Gynecomastia 
may develop with spironolactone treatment. The 
development of gynecomastia appears to be related 
to the dosage level and duration of therapy and is 
reversible with discontinuation. In rare instances, 
breast enlargement may persist when spironolactone 
is discontinued. Although the results are impressive 
the cases have confounding factors. For example, 7 
of the patients initiated contraceptive therapy at the 
same time.
As documented in the early literature, a similar 
hormone blocker, cyproterone acetate, has been 
used frequently for the treatment of HS. Multiple 
studies have demonstrated that spironolactone 
and cyproterone acetate may be equivalent in 
efficacy, although large-scale studies are lacking 
[33]. Cyproterone acetate is unavailable in the United 
States.
Oral Contraceptive Pills
Although the relationship with endocrine 
abnormalities is not clear, some patients suffer from 
hormonal irregularities that contribute to their HS. 
Establishing whether a patient with HS has irregular 
hormone levels, irregular periods, or polycystic ovarian 
syndrome is important in understanding the patient’s 
HS pathophysiology and treatment options. Female 
patients have anecdotally reported that combination 
progesterone/estrogen oral contraceptive pills 
(OCPs) with a high estrogen to progesterone 
ratio and low androgenicity of progesterone have 
ameliorated their disease symptoms [16]. On the 
other hand, isolated case reports have suggested a 
link between oral contraceptive pill use and HS [34]. 
In the absence of more thorough studies, there is 
little evidence supporting or refuting the effects of 
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oral contraceptives on HS. Regardless, the current use 
of oral contraceptives is mainly based on anecdotal 
evidence and the supportive evidence for OCP use 
in acne. If oral contraceptives are considered, those 
containing ethinyl estradiol and drospirenone 
are preferred, combined with the antiandrogen 
spironolactone, 50 to 100 mg, when possible [16]. 
Overall, supportive data is lacking regarding the 
use oral contraceptives in HS and more research is 
needed.
Differences in Men versus Women
HS affects men and women differently. In the United 
States HS is more common among women [35]. 
However, in some countries, such as Tunisia, HS is 
more common in men [36]. The disease presentation 
itself varies between men and women as well. Women 
are more likely to have axillary involvement, whereas 
men have perineal and perianal lesions. However, HS 
can occur in any area of the body in men and women. 
The differences may be attributed to a variety of 
factors such as follicular trauma, shaving, hormone 
levels, skin microbiome, adipose tissue, and lifestyle 
(such as choice of soap and clothing). In addition, the 
fact that women seek medical care more often than 
men in the United States may be a confounding factor 
[37]. Regarding treatment, both men and women 
have reported improvements with all three of the 
anti-androgen medications: finasteride, dutasteride, 
and spironolactone [8,9,32]. Studies have yet to 
report differences in response rates between the 
sexes to the three hormonal therapies.
Conclusion
HS is a chronic, debilitating inflammatory skin disease 
that may progress from painful papules and nodules 
to abscess formation and permanent scarring. 
Although the pathogenesis is unclear, endocrine 
involvement has been suggested owing to symptom 
variation during menstrual cycle and pregnancy. 
Additionally, HS in women may be promoted by 
hyperandrogenism, but the data are conflicting. The 
lack of understanding of HS pathogenesis makes it 
challenging to treat. There is not a recommended 
“gold standard” treatment; typically, individuals 
have to try various treatment modalities. Data on 
the precise effects of hormonal therapies (anti-
androgens and OCPs) in individuals with HS are 
limited. It is theorized that anti-androgens decrease 
the local concentration of DHT and may also alter 
end-organ sensitivity to circulating androgens. Some 
individuals have achieved relief with anti-androgen 
therapies, but the data on OCP use in HS treatment 
is conflicting. If OCPs are considered as a treatment 
modality, combination therapy with the anti-
androgen spironolactone is advised. Our manuscript 
highlights the need for large scale randomized 
controlled trials to improve the evidence base for 
the use of hormonal therapies in HS. Additionally, 
further understanding of HS pathogenesis may lead 
to greater treatment options.
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